20 filings
8-K
VIE
Viela Bio, Inc.
15 Mar 21
Completion of Acquisition or Disposition of Assets
9:02am
8-K
VIE
Viela Bio, Inc.
4 Mar 21
Departure of Directors or Certain Officers
4:06pm
8-K
VIE
Viela Bio, Inc.
1 Mar 21
Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
4:11pm
8-K
VIE
Viela Bio, Inc.
16 Feb 21
Results of Operations and Financial Condition
12:00am
8-K
VIE
Viela Bio, Inc.
1 Feb 21
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio
7:21am
8-K
vq2z wghzo8x
8 Dec 20
Departure of Directors or Certain Officers
4:06pm
8-K
bqc4vdqt
10 Nov 20
Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights
4:20pm
8-K
uxaxnc
5 Nov 20
Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
4:20pm
8-K
ugr1ja5
15 Sep 20
Departure of Directors or Certain Officers
4:01pm
8-K
mmelv05xmj2q
12 Aug 20
Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights
4:20pm
8-K
38dssnhm35y
19 Jun 20
Submission of Matters to a Vote of Security Holders
4:55pm
8-K
w73t366r hce801lr
12 Jun 20
Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the UPLIZNA™ is the first and only B cell depleter approved for the treatment of NMOSD in adults
12:00am
8-K
g9cd66 wbw
13 May 20
Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights
4:25pm
8-K
51v n3wdo
30 Apr 20
Viela Bio Announces Election of Rachelle Jacques to its Board of Directors
4:27pm
8-K
0z0wxnze
25 Mar 20
Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
4:25pm
8-K
e7z9c0v
10 Jan 20
Regulation FD Disclosure
4:15pm
8-K
c5k84kzjltst 1w
11 Dec 19
Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome
7:22am
8-K
k4isgk
14 Nov 19
Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights
4:05pm
8-K
0wf93h0jlnufi0 x1u
9 Oct 19
Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions
7:25am
8-K
wsurpja
7 Oct 19
Viela Bio Announces Closing of Initial Public Offering
5:00pm
- Prev
- 1
- Next